Company Further Examining the Pursuit of the World's First Oral Liraglutide Product KELOWNA, BC / ACCESS Newswire / February 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce final results from Human Pilot Study #5 (GLP-1-H25-5) (the "Study"), which compared oral DehydraTECH-liraglutide ("DHT-LIR") capsules to injected Saxenda® branded liraglutide ("SAX-LIR"). "We are extremely pleased with the results of Huma ...

Core Viewpoint - Lexaria Bioscience Corp. has achieved a significant milestone by securing a total of 60 valid patents globally, enhancing its intellectual property portfolio and positioning itself for future commercial opportunities [1][9]. Patent Developments - The company has successfully obtained 6 new patents since its last update on October 9, 2025, indicating a proactive approach to intellectual property development [2]. - In Patent Family 20, Lexaria received its first patent in Australia for sublingual delivery of nicotine, complementing existing patents in the US, Canada, and Japan [3]. - The company has also secured its first European Union patent in Patent Family 21 for treating hypertension, which is significant given that Europe is the second-largest hypertension market globally [4]. - In Patent Family 24, Lexaria has strengthened its position with 2 new Australian patents and 1 new European Union patent for treating epilepsy, bringing the total to 6 US patents, 4 Australian patents, and 1 European Union patent [5]. - Additionally, in Patent Family 27, Lexaria has received 1 new US patent for treating diabetes, now holding 2 US patents in this family, which is crucial due to recent successes in the GLP-1 sector [6]. Research and Development - Lexaria's innovations are supported by a rigorous process that includes research, animal and human testing, and subsequent patent applications, allowing the company to pursue commercial relationships post-patent grants [7]. Shareholder Engagement - The company is reminding shareholders to vote in the upcoming Annual Meeting scheduled for January 27, 2026, emphasizing the importance of shareholder participation [8][10].

Financial Performance - The company reported a revenue of $2.5 billion for Q2 2023, representing a 15% year-over-year increase[1]. - The company provided guidance for Q3 2023, expecting revenue to be between $2.6 billion and $2.8 billion, indicating a potential growth of 8% to 12%[3]. - Revenue from B2B sales for the three months ended November 30, 2025, was $183,923, a decrease of $9,923 compared to the same period in 2024, reflecting a shift away from B2B clients towards pharmaceuticals[136]. - The company reported a net loss of $1,597,503 for the three months ended November 30, 2025, compared to a net loss of $2,706,628 for the same period in 2024, indicating a reduction in losses year-over-year[131]. - The company incurred a net loss of $1,595,712 for the three months ended November 30, 2025, compared to a net loss of $2,706,628 for the same period in 2024[146]. - Net cash used in operating activities was approximately $1.0 million for the three months ended November 30, 2025, a significant decrease from $2.7 million in the same prior year period[143]. Research and Development - The company completed a Phase 1b clinical study showing good safety and tolerability of DehydraTECH formulated cannabidiol and semaglutide, with clear reductions in adverse events compared to the Rybelsus® control arm[117]. - Lexaria's DehydraTECH technology improves the delivery of Active Pharmaceutical Ingredients (APIs), potentially lowering overall dosing and enhancing bioavailability across various product categories[110]. - The company anticipates ongoing clinical research programs in cardiometabolic health, particularly for diabetes and weight loss treatments[113]. - The FDA provided a Study May Proceed letter for the IND application related to DehydraTECH-CBD for hypertension, allowing the company to advance its clinical trials[124]. - The company completed a human study (GLP-1-H24-4) with over 100 participants, demonstrating good safety and tolerability of DehydraTECH formulations compared to the Rybelsus® control arm[121]. - Long-term stability testing of DehydraTECH compositions is ongoing, with positive findings meeting internal expectations for chemical and microbiological purity[123]. - The company is exploring various therapeutic indications for DehydraTECH, including diabetes and weight loss treatments, with ongoing R&D programs[120]. - Research and development expenses increased by 12%, focusing on innovative technologies for product enhancement[7]. - Research and development expenditures decreased by $1,281,880 year-over-year for the three months ended November 30, 2025, as the company neared completion of its Phase 1b Clinical Trial[137]. Intellectual Property and Acquisitions - The company has several patents pending worldwide, specifically for the use of DehydraTECH with GLP-1/GIP drugs and cannabinoids for treating diabetes and heart disease[113]. - Lexaria's patent portfolio includes granted patents related to food and beverage compositions infused with lipophilic active agents, enhancing the effectiveness of API delivery[116]. - The company plans to continue seeking beneficial acquisitions of intellectual property to expand its portfolio[114]. - A strategic acquisition of a smaller competitor was completed, expected to contribute an additional $300 million in annual revenue[6]. Market Strategy and Expansion - The company is expanding its market presence in Asia, targeting a 20% increase in sales in the region by the end of 2024[5]. - New product launches included a line of enhanced delivery systems for lipophilic active agents, projected to increase market share by 5%[4]. - A new marketing strategy was implemented, aiming to boost brand awareness and customer engagement by 30% over the next year[9]. Financial Position and Funding - The company raised $3.4 million in net proceeds from a Registered Direct offering that closed in September 2025[132]. - The company has incurred recurring losses and negative cash flows from operations, with expectations of increased expenditures related to ongoing R&D programs, particularly for GLP-1 drugs and hypertension treatments[130]. - The company expects its current cash resources to fund operations through the first quarter of fiscal year 2027, but there is substantial doubt about its ability to continue as a going concern[133]. - The company plans to fund operations through equity financing arrangements and potential collaborations or strategic partnerships[149]. - Share issuance costs of $0.6 million were charged to additional paid-in capital during the recent financing[111]. - As of November 30, 2025, the company had current assets of $5,363,129 and current liabilities of $1,456,534, resulting in net working capital of $3,906,595[141]. - Cash and cash equivalents as of November 30, 2025, were approximately $4.3 million, which is expected to be insufficient to meet financial obligations for the next twelve months[149]. Operational Efficiency - The company reported a 25% increase in gross margin, attributed to improved operational efficiencies[8]. - Other general and administrative expenses decreased by $197,558, mainly due to lower spending on advertising and promotions[140]. - Consulting fees and salaries increased by $31,272 year-over-year, primarily due to cost of living adjustments, offset by reduced consulting fees and lower stock-based compensation[138]. - Legal and professional fees rose by $149,887 during the three months ended November 30, 2025, due to higher accounting and professional fees related to financing activities[139].

Core Insights - Lexaria Bioscience Corp. has made significant advancements in oral drug delivery technology, particularly in the GLP-1 sector, utilizing its proprietary DehydraTECH™ (DHT) technology [3][11][60] - The company reported a substantial increase in the market for GLP-1 drugs, with worldwide revenues rising from $34.4 billion in 2024 to $51.9 billion in 2025, marking a 51% year-over-year growth [8] - Lexaria's DHT technology has shown promising results in reducing adverse events (AEs) associated with GLP-1 drugs, which are primarily injectable, thus presenting a significant market opportunity [12][14][58] 2025 Highlights - In 2025, Lexaria focused its resources on studying its DHT technology with the three leading GLP-1 drugs: semaglutide, tirzepatide, and liraglutide [5][6] - The company completed its first Phase 1b registrational study in Australia, achieving a gross total of $9.5 million through three equity raises [6][49] - Lexaria's DHT technology demonstrated positive results across all R&D studies conducted in 2025, including significant reductions in AEs [6][58] Market Dynamics - The GLP-1 drug market is becoming increasingly competitive, with new companies and products emerging regularly, and existing drugs expanding their indications beyond diabetes and weight loss [9] - Despite the overall market growth, the orally-delivered segment of GLP-1 drugs has seen limited revenue growth, with only 5% of total revenues from oral products in 2025 [10] Research and Development - Lexaria's studies in 2025 included Human Pilot Studies that showed DHT-processed drugs had reduced AEs compared to their injectable counterparts, with notable reductions in gastrointestinal issues [18][29] - The company plans to leverage findings from its 2025 studies to design new R&D work in 2026, focusing on improving oral GLP-1 formulations [34][36] Collaboration and Business Development - Lexaria has extended its Material Transfer Agreement (MTA) with a pharmaceutical partner to evaluate DHT technology, allowing for continued collaboration and strategic planning [41][43] - The company is actively pursuing discussions with various pharmaceutical companies for potential partnerships, not only in the GLP-1 sector but also in other therapeutic areas [46][48] Financial Overview - Lexaria raised $9.5 million in 2025, successfully capitalizing on favorable market conditions to fund its R&D activities through 2026 [49][50] - The company has sufficient funding to support its operations and marketing campaigns in 2026, despite previous stock price weaknesses [55][56] Future Outlook - Lexaria aims to develop the world's first oral version of liraglutide using DHT and is exploring additional R&D opportunities outside the GLP-1 sector [63][40] - The company is committed to advancing its DHT technology and believes it is closer to a commercial breakthrough than ever before [60][61]

Core Insights - Lexaria Bioscience Corp. has released additional data from its Phase 1b clinical study GLP-1-H24-4, which focuses on the efficacy of its DehydraTECH™ technology compared to Rybelsus® [1][2] Secondary Efficacy Parameters - At week 16, the DHT arms showed no statistically significant differences compared to the Rybelsus® control in mean fasting glucose, cholesterol, and LDL cholesterol [3] Body Composition - The DHT-semaglutide arm showed a modest reduction in fat mass of -1.08 kg and total mass of -1.40 kg, while the Rybelsus® control arm achieved greater reductions of -3.55 kg in fat mass and -5.36 kg in total mass, with a higher reduction in lean mass of -1.72 kg [4] Blood Pressure Analyses - The DHT-CBD arm achieved significant reductions in blood pressure, with a mean change of -4.6 mmHg in systolic and -4.0 mmHg in diastolic blood pressure at week 4 [5][6] Pharmacokinetic Exploratory Analyses - Plasma CBD concentrations were quantifiable through week 16 in the DHT-CBD arms, while semaglutide concentrations were not quantifiable due to assay issues, although preliminary tests indicated measurable levels [8] Health Survey Results - Participants in the DHT-semaglutide arm reported mean improvements of over 5 points in physical components and over 3 points in mental components of the SF-36 health survey, compared to modest improvements in the Rybelsus® control arm [9][10] Overall Conclusions and Next Steps - The study met its primary endpoint, demonstrating good safety and tolerability of all DHT test articles, with positive findings across various parameters compared to Rybelsus® [11] Future Plans - Lexaria plans to pursue further clinical testing with a DHT + SNAC + semaglutide composition and is in discussions with a pharmaceutical company regarding the dataset from the study [15][17][18]

Core Insights - Softbank has completed its $40 billion investment commitment to OpenAI, with a final investment of $22 billion to $22.5 billion sent last week [1] - The total investment includes a previous $10 billion syndicated and $8 billion directly invested in OpenAI [1] - The investment values OpenAI at a pre-money valuation of $260 billion [1] Funding Details - The funding will be disbursed over a 12 to 24 month period [2] - Part of the investment is intended to support OpenAI's artificial intelligence infrastructure through the Stargate joint venture with Oracle and Softbank [2]

Core Viewpoint - Air China and its subsidiary have signed an agreement with Airbus to purchase 60 A320NEO jets, valued at approximately $9.5 billion at list prices [1] Company Summary - Air China is expanding its fleet by acquiring 60 A320NEO jets from Airbus [1] - The total value of the deal is around $9.5 billion, indicating a significant investment in modernizing and expanding its aircraft capabilities [1] Industry Summary - The agreement reflects ongoing demand for new aircraft in the aviation industry, particularly for fuel-efficient models like the A320NEO [1] - This purchase may enhance Air China's competitive position in the market as airlines increasingly focus on sustainability and operational efficiency [1]

SoftBank Group has completed its $40 billion investment in OpenAI, CNBC reported on Tuesday, citing people familiar with the matter. ...

Lexaria Bioscience Corp. (NASDAQ:LEXX) on Tuesday provided an update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH ( DHT) study arms relative to the Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (semaglutide) control study arm.“We are extremely pleased to not only have successfully achieved our primary endpoint,” stated Richard Christopher, CEO of Lexaria, “but to have also demonstrated obvious superiority in reducing unwanted side effects by as much ...

Core Insights - Lexaria Bioscience Corp. has successfully achieved its primary endpoint in the Phase 1b study GLP-1-H24-4, demonstrating significant efficacy in reducing unwanted side effects compared to Rybelsus® [2][13] - The company raised a total of $7.5 million through financing activities, which will support new development opportunities throughout 2026 [2][18] - The study results indicate that DehydraTECH-semaglutide reduced overall side effects by 48% and gastrointestinal side effects by 55% compared to Rybelsus® [4][6] Study Results - All four DehydraTECH (DHT) test articles were found to be safe and well-tolerated, meeting the primary endpoint objective [3][13] - The total adverse events (AEs) for DHT-semaglutide were reduced by 47.9% compared to Rybelsus®, with a statistically significant reduction in gastrointestinal AEs [6][10] - The study included 126 participants, focusing on safety and tolerability, with DHT-semaglutide showing the best performance among the tested formulations [19] Efficacy Assessments - The primary efficacy endpoint of HbA1c reduction showed comparable performance between DHT-semaglutide and Rybelsus®, with no statistically significant difference [10][11] - Bodyweight reduction was more pronounced in the Rybelsus® control arm compared to all DHT arms, raising questions about the differing results [11][12] - The study's findings suggest that even small reductions in HbA1c can improve cardiovascular outcomes in overweight or obese individuals [10] Future Directions - Lexaria plans to investigate the DHT-semaglutide formulation further, potentially incorporating salcaprozate sodium (SNAC) in future studies [14][15] - The company aims to relay the study dataset to its pharmaceutical partner under a Material Transfer Agreement, which has been extended to April 30, 2026 [16][17] - Additional non-primary endpoint results are expected to be released soon, providing further insights into the study's findings [20]